1. Home
  2. BWB vs ALT Comparison

BWB vs ALT Comparison

Compare BWB & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bridgewater Bancshares Inc.

BWB

Bridgewater Bancshares Inc.

HOLD

Current Price

$20.83

Market Cap

571.1M

Sector

Finance

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$3.41

Market Cap

573.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BWB
ALT
Founded
2005
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
571.1M
573.8M
IPO Year
2018
2005

Fundamental Metrics

Financial Performance
Metric
BWB
ALT
Price
$20.83
$3.41
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$21.67
$17.67
AVG Volume (30 Days)
84.7K
3.1M
Earning Date
04-21-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
44.66
25.37
EPS
1.03
N/A
Revenue
N/A
$41,000.00
Revenue This Year
$24.57
N/A
Revenue Next Year
$12.35
N/A
P/E Ratio
$20.31
N/A
Revenue Growth
N/A
105.00
52 Week Low
$16.06
$2.56
52 Week High
$22.62
$6.44

Technical Indicators

Market Signals
Indicator
BWB
ALT
Relative Strength Index (RSI) 42.55 55.74
Support Level $20.81 $3.18
Resistance Level $22.01 $3.32
Average True Range (ATR) 0.56 0.13
MACD -0.07 -0.01
Stochastic Oscillator 28.96 36.67

Price Performance

Historical Comparison
BWB
ALT

About BWB Bridgewater Bancshares Inc.

Bridgewater Bancshares Inc is a financial holding company. Through its subsidiary, it offers various personal and commercial banking products and services such as savings accounts, certificates of deposits, money transfer services, digital wallets, credit and debit cards, safe deposit lockers, different types of loans and advances, commercial deposit accounts, treasury management, and others. The company principally focuses on catering to commercial clients, offering a suite of loan and deposit products. Geographically, it mainly operates in the Twin Cities Metropolitan Statistical Area in the United States.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: